Voya Investment Management LLC Vaxcyte, Inc. Transaction History

Voya Investment Management LLC

$71.9 Billion
Q1 2025

A detailed history of Voya Investment Management LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 306,729 shares of PCVX stock, worth $9.98 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

306,729

Previous 301,560 1.71%

Holding current value

$9.98 Million

Previous $24.7 Million 53.08%

% of portfolio

0.02%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$37.76 - $92.13 $195,181 - $476,219	5,169 Added 1.71%	306,729 $11.6 Million
Q4 2024 Feb 14, 2025	SELL	$80.97 - $117.93 $187,769 - $273,479	-2,319 Reduced 0.76%	301,560 $24.7 Million
Q3 2024 Feb 07, 2025	BUY	$70.52 - $117.12 $1.12 Million - $1.86 Million	15,873 Added 5.51%	303,879 $34.7 Million
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $1.03 Million - $1.7 Million	14,550 Added 5.21%	293,948 $33.6 Million
Q2 2024 Feb 07, 2025	BUY	$60.06 - $78.77 $5.91 Million - $7.75 Million	98,338 Added 51.85%	288,006 $21.7 Million
Q2 2024 Dec 03, 2024	SELL	$60.06 - $78.77 $873,873 - $1.15 Million	-14,550 Reduced 4.95%	279,398 $21.1 Million
Q2 2024 Aug 14, 2024	BUY	$60.06 - $78.77 $5.78 Million - $7.58 Million	96,267 Added 52.57%	279,398 $21.1 Million
Q1 2024 Feb 07, 2025	SELL	$59.79 - $81.05 $6.23 Million - $8.45 Million	-104,280 Reduced 35.48%	189,668 $13 Million
Q1 2024 Dec 06, 2024	SELL	$59.79 - $81.05 $6.63 Million - $8.98 Million	-110,817 Reduced 37.7%	183,131 $12.5 Million
Q1 2024 May 15, 2024	BUY	$59.79 - $81.05 $346,243 - $469,360	5,791 Added 3.27%	183,131 $12.5 Million
Q4 2023 Feb 07, 2025	BUY	$45.35 - $63.41 $62,764 - $87,759	1,384 Added 0.76%	183,877 $11.5 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $59,952 - $83,828	1,322 Added 0.75%	177,340 $11.1 Million
Q3 2023 Feb 07, 2025	BUY	$46.0 - $53.1 $931,040 - $1.07 Million	20,240 Added 12.47%	182,493 $9.3 Million
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $931,040 - $1.07 Million	20,240 Added 12.99%	176,018 $8.97 Million
Q2 2023 Feb 07, 2025	BUY	$34.66 - $54.07 $4.14 Million - $6.46 Million	119,464 Added 279.19%	162,253 $8.1 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $3.92 Million - $6.11 Million	112,989 Added 264.06%	155,778 $7.78 Million
Q1 2023 Feb 07, 2025	SELL	$36.27 - $47.2 $9.11 Million - $11.9 Million	-251,159 Reduced 85.44%	42,789 $1.6 Million
Q4 2022 Feb 07, 2025	BUY	$20.58 - $47.95 $456,299 - $1.06 Million	22,172 Added 107.54%	42,789 $2.05 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $456,299 - $1.06 Million	22,172 Added 107.54%	42,789 $2.05 Million
Q3 2022 Feb 07, 2025	SELL	$21.69 - $28.53 $5.93 Million - $7.8 Million	-273,331 Reduced 92.99%	20,617 $494,000
Q3 2022 Mar 03, 2023	SELL	$21.69 - $28.53 $480,910 - $632,567	-22,172 Reduced 51.82%	20,617 $494,000
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $18,610 - $24,478	858 Added 4.34%	20,617 $495,000
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $66,087 - $99,356	3,738 Added 23.33%	19,759 $430,000
Q4 2021 Feb 14, 2022	BUY	$19.32 - $26.45 $6,201 - $8,490	321 Added 2.04%	16,021 $381,000
Q2 2021 Aug 16, 2021	BUY	$16.45 - $24.06 $57,147 - $83,584	3,474 Added 28.41%	15,700 $353,000
Q1 2021 May 17, 2021	BUY	$18.66 - $29.16 $84,492 - $132,036	4,528 Added 58.82%	12,226 $241,000
Q4 2020 Feb 16, 2021	BUY	$26.57 - $51.74 $49,021 - $95,460	1,845 Added 31.52%	7,698 $205,000
Q3 2020 Nov 16, 2020	SELL	$26.5 - $55.4 $5.31 Million - $11.1 Million	-200,469 Reduced 97.16%	5,853 $289,000
Q2 2020 Aug 14, 2020	BUY	$26.15 - $35.45 $5.4 Million - $7.31 Million	206,322 New	206,322 $6.52 Million

Others Institutions Holding PCVX

# of Institutions

344

Shares Held

136M

Call Options Held

348K

Put Options Held

250K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $1.93B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.

Account

Voya Investment Management LLC Vaxcyte, Inc. Transaction History